HIV-vaccine Research and Development in Thailand: Evolution and challenges

被引：15

作者：

Pitisuttithum, Punnee ^{[1
]}

Choopanya, Kachit ^{[2
]}

Rerk-Ngnam, Supachai ^{[3
]}

机构：

[1] Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand

[2] Taksin Hosp, Bangkok Tenofovir Study Grp, Bangkok 10600, Thailand

[3] Minist Publ Hlth, Dept Dis Control, Nonthaburi 11000, Thailand

来源：

VACCINE | 2010年 / 28卷

基金：

美国国家卫生研究院;

关键词：

Challenges; HIV-vaccine trials; Thailand; INJECTION-DRUG USERS; IMMUNODEFICIENCY-VIRUS TYPE-1; SUBTYPE-E; CANDIDATE VACCINE; EFFICACY TRIAL; BANGKOK; IMMUNOGENICITY; SAFETY; INFECTION; PRIME;

D O I：

10.1016/j.vaccine.2009.08.061

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Thailand has been committed to HIV-Vaccine Research and Development since the launch of its National Plan, in 1993. Series of phase I/II trials, and two phase III clinical trials, have been conducted. The first efficacy trial was conducted with a high-risk group, injecting drug users (IDUs), and the second involved communities in the Eastern-seaboard provinces of Thailand. Both involved similar challenges in terms of infrastructure strengthening, capacity building, implementing the trials into the existing health system, staffing, and commitments. However, there were different issues in recruitment process, follow up, social impact events and community involvement since the target participants were different. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：B45 / B49

页数：5

共 36 条

[1]

[Anonymous], 2008, REP GLOB AIDS EP

[2] Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1 [J].

Berman, PW ;

Murthy, KK ;

Wrin, T ;

Vennari, JC ;

Cobb, EK ;

Eastman, DJ ;

Champe, M ;

Nakamura, GR ;

Davison, D ;

Powell, MF ;

Bussiere, J ;

Francis, DP ;

Matthews, T ;

Gregory, TJ ;

Obijeski, JF .

JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :52-59

[3] HIV vaccine design and the neutralizing antibody problem [J].

Burton, DR ;

Desrosiers, RC ;

Doms, RW ;

Koff, WC ;

Kwong, PD ;

Moore, JP ;

Nabel, GJ ;

Sodroski, J ;

Wilson, IA ;

Wyatt, RT .

NATURE IMMUNOLOGY, 2004, 5 (03) :233-236

[4] Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? [J].

Esparza, J ;

Bhamarapravati, N .

LANCET, 2000, 355 (9220) :2061-2066

[5]

Francis DP, 1998, AIDS RES HUM RETROV, V14, pS325

[6]

FRANCIS DP, 2006, HIV VACCINE RES DEV, P265

[7]

KAEWKUNGWAL J, 2008, AIDS 2008

[8] Sexual Behavior and Risk Factors for HIV Infection Among Homosexual and Bisexual Men in Thailand [J].

Li, Andrea ;

Varangrat, Anchalee ;

Wimonsate, Wipas ;

Chemnasiri, Tareerat ;

Sinthuwattanawibool, Chalinthorn ;

Phanuphak, Praphan ;

Jommaroeng, Rapeepun ;

Vermund, Sten ;

van Griensven, Frits .

AIDS AND BEHAVIOR, 2009, 13 (02) :318-327

[9] Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand [J].

MacQueen, KM ;

Vanichseni, S ;

Kitayaporn, D ;

Lin, LS ;

Buavirat, A ;

Naiwatanakul, T ;

Raktham, S ;

Mock, P ;

Heyward, WL ;

Des Jarlais, DC ;

Choopanya, K ;

Mastro, TD .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03) :243-251

[10]

MARTIN M, 2004, 15 INT AIDS C

← 1 2 3 4 →